Phase III trials of NX 1207 for BPH fail to meet endpoints-Nymox Pharma

Two Phase III US studies (NX02-0017 and NX02-0018) of NX 1207, from Nymox Pharmaceutical, for the treatment of Benign Prostate Hyperplasia, failed to meet their primary efficacy endpoints. Drug safety was acceptable. Drug efficacy reached levels similar to earlier studies but was not statistically significant in comparison to the placebo control due to a higher placebo response than in earlier NX 1207 studies and in other placebo-controlled BPH studies. The compound remains promising for low grade localized prostate cancer where the Phase II results showed evidence that NX 1207 treatment had a positive effect on biopsy results and clinical and biochemical progression. Full results will be reported at a later date.